On December 19, 2024, the Food and Drug Administration carried out an inspection of Biomat USA, Inc. in Portland, reviewing its handling of blood and blood products, according to data posted on the FDA’s website.
The FDA’s final report concluded that Biomat USA, Inc. is not required to implement any corrective actions regarding its management operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
